A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults With Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)

This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18 years of age with ventilated HABP or VABP.

开始日期2025-06-01

申办/合作机构

Venatorx Pharmaceuticals, Inc.

[+1]

NCT04951505

/ Completed临床1期

A Phase 1 Study to Evaluate the Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects

This is a single-center, open-label study to assess the safety and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy adult male and female subjects. Thirty subjects will receive a total of 6 doses of cefepime-taniborbactam (2 g cefepime/0.5g taniborbactam) administered intravenously every 8 hours. Following the sixth dose of cefepime-taniborbactam, subjects will be assigned to one of six bronchoscopy sampling times.

开始日期2021-06-29

申办/合作机构

Venatorx Pharmaceuticals, Inc.

CTR20191681

/ Completed临床1期

头孢吡肟/VNRX-5133在中国健康受试者中单剂和多剂静脉输注给药的药代动力学、安全性和耐受性的1期临床试验

1. 评价中国健康受试者中头孢吡肟/VNRX-5133单剂和多剂静脉（IV）输注给药的药代动力学。 2. 评价中国健康受试者中头孢吡肟/VNRX-5133单剂和多剂静脉输注给药的安全性和耐受性。

开始日期2020-06-06

申办/合作机构

Lyophilization Services of New England, Inc.

[+2]

100 项与头孢吡肟/他尼硼巴坦相关的临床结果

登录后查看更多信息

100 项与头孢吡肟/他尼硼巴坦相关的转化医学

登录后查看更多信息

100 项与头孢吡肟/他尼硼巴坦相关的专利（医药）

登录后查看更多信息

829

项与头孢吡肟/他尼硼巴坦相关的文献（医药）

2025-10-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Rapid detection of cefepime-taniborbactam susceptibility/resistance in Enterobacterales

Article

作者: Nordmann, Patrice ; Le Terrier, Christophe ; Poirel, Laurent ; Kerbol, Auriane ; Bouvier, Maxime

OBJECTIVE:

Metallo-β-lactamase-producing Enterobacterales is widely distributed and confers resistance to all β-lactams, including carbapenems. Recently, a cefepime-taniborbactam combination has been developed that aims to provide a treatment option for infections caused by metallo-β-lactamase-producing bacteria. The objective of this study was to develop a rapid diagnostic test, namely the Rapid Cefepime-Taniborbactam NP test, for the early identification of cefepime-taniborbactam susceptibility or resistance in Enterobacterales.

METHODS:

The Rapid Cefepime-Taniborbactam NP test is based on the detection of glucose metabolism resulting from bacterial growth, detectable by a change in colour of a red phenol (from red to yellow) in the presence of cefepime-taniborbactam. A total of 103 Enterobacterales isolates, including 94 carbapenemase producers, were selected for evaluation of the performance of the Rapid Cefepime-Taniborbactam NP test. In the absence of available breakpoints, two provisional breakpoints were taken for the interpretation-one corresponding to the current Clinical and Laboratory Standards Institute cefepime resistance breakpoint (R ≥ 16 mg/L) and one following current literature on this combination (R ≥ 32 mg/L).

RESULTS:

The test demonstrated a sensitivity and specificity of 95% and 98%, respectively, following a resistance breakpoint of ≥16 mg/L. When considering a resistance breakpoint of ≥32 mg/L, the sensitivity and specificity were found to be 100% and 91%, respectively. All results were obtained within a 3 h incubation period at 35°C ± 2°C, representing a significant reduction in time compared with current antimicrobial susceptibility testing methods.

CONCLUSIONS:

The results of this study demonstrate that the Rapid Cefepime-Taniborbactam NP test is a highly accurate and time-efficient technique for the detection of bacterial resistance.

2025-08-07·AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

A Retrospective Analysis of Bacterial Infections (2021–2024) in a Reference Laboratory in Kathmandu, Nepal

Article

作者: Adhikari, Jeevan ; Shrestha, Ranjan Bhele ; Basnet, Ajaya ; Bajracharya, Sohani

Of all the recognized public health threats, antimicrobial resistance (AMR) is among the most serious. Antimicrobial resistance may have a higher prevalence in low- and middle-income countries, where antimicrobial misuse is compounded by inadequate infection control measures. In this study, we examined AMR trends in bacterial infections in a reference laboratory in Kathmandu, Nepal, from 2021 to 2024. We collected the clinical records of infected patients, including demographic details, pathogen profiles, and antibiograms, from the electronic laboratory information system and analyzed them using SPSS version 17.0 (IBM Corp., Armonk, NY). Among 3,720 patients, 703 (19.7%; median age: 40 years; 395 [54.0%] female) had infections primarily caused by bacteria (91.7%; 723/731), followed by yeast (3.8%; 28/731). Urinary tract infections (55.9%; 290/703) were the most common. The predominant pathogen was Escherichia coli (41.3%; 290/703). Resistance rates in Enterobacterales, nonfermenters, and Gram-positive cocci were 31.0%, 43.4%, and 13.5%, respectively, for aminoglycosides; 49.7%, 42.8%, and 40.2%, respectively, for fluoroquinolones; 64.9%, 59.0%, and 65.6%, respectively, for cephalosporins; 47.3%, 77.4%, and 27.2%, respectively, for trimethoprim–sulfamethoxazole; and 83.0%, 100.0%, and 85.0%, respectively, for penicillins. Extensively drug-resistant (XDR; 19.1%; 134/703) and multidrug-resistant (29.2%; 205/703) bacteria exhibited >90% resistance to ciprofloxacin, erythromycin, and beta-lactams. Over time (2022–2024), resistance increased for aminoglycosides (27.7–32.3%), fluoroquinolones (43.5–54.1%), and penicillin with beta-lactamase inhibitors (PwBLIs; 35.9–58.7%) but decreased for cephalosporins (67.5–62.8%), carbapenems (23.3–18.7%), penicillins (85.2–82.1%), trimethoprim–sulfamethoxazole (59.6–42.2%), and nitrofurantoin (39.0–3.7%). A low rate of bacterial infections was detected among hospital visitors. Urinary tract infections were the most prevalent type of infection. Multidrug-resistant bacteria predominated over XDR bacteria. Resistance to beta-lactams declined over time; however, resistance to aminoglycosides, fluoroquinolones, and PwBLIs increased.

2025-08-05·Microbiology Spectrum

Shifts in bla genes and Class 1 integron prevalence in beta-lactamase-producing bacteria before and after the COVID-19 pandemic in Mendoza, Argentina

Article

作者: Rathour, V. S. ; Contreras, L. ; Zuloaga, L. ; Dominguez, S. ; Secotaro, A. ; Nolly, M. B. ; Márquez-Friedrichs, F. ; Sánchez, D. G. ; Ferreyra, A. ; Damiani, M. T.

ABSTRACT:

This study analyzes the molecular epidemiology of bla genes and Class 1 integron in broad-spectrum beta-lactamase (BSBL) and extended-spectrum beta-lactamase (ESBL) producing strains of bacteria isolated from clinical samples of hospitalized and ambulatory patients before and after the COVID-19 pandemic. Isolates obtained in two periods were compared: the first corresponding to the years November 2019–March 2020, and the second to the years November 2021–April 2022. We evaluate changes in resistance patterns of antibiotics associated with pressures on the healthcare system and social lockdowns. A total of 156 isolates were analyzed: 78 from the first period (61 hospitalized, 17 ambulatory) and 78 from the second period (47 hospitalized, 31 ambulatory). Escherichia coli and Klebsiella pneumoniae were the predominant bacterial species, representing 85% of the isolates in both periods. The frequency of ambulatory ESBL-producing isolates increased significantly, from 22% (17/78) to 40% (31/78; P < 0.01) in the second period. The prevalence of blaSHV increased from 24% (19/78) to 72% (56/78; P < 0.01) in the second period, while the blaCTX-M-2 group, absent in the first period, was detected in 43% (34/78) of isolates from the second period. Strains from the second period exhibited greater genetic complexity, with an increased prevalence of combinations involving three or more bla genes, including isolates carrying up to five of such genes. Class 1 integron showed a strong correlation with resistance to ciprofloxacin and trimethoprim-sulfamethoxazole. The gene blaOXA-1 , previously associated with resistance to beta-lactamase inhibitors, did not show a clear pattern in the second period.

IMPORTANCE:

Antimicrobial resistance associated with the production of extended-spectrum beta-lactamase (ESBL) represents a critical global health challenge, particularly due to the limited development of new antibiotics. This is the first report from Argentina’s central-west region examining the prevalence of beta-lactamase-encoding genes, providing a framework for future research. Our findings reveal a significant increase in bacteria with the ESBL phenotype, particularly among ambulatory populations post-pandemic, suggesting a concerning spread of multidrug-resistant bacteria outside hospital environments. This could compromise empirical antibiotic treatments for ambulatory patients, increasing the risk of severe complications. Our results highlight the urgent need for ongoing surveillance to detect virulent strains before clonal spread or horizontal gene transfer occurs in the community. They also emphasize the importance of strategies to ensure the prudent use of antimicrobials and mitigate the increasing prevalence of resistance genes, which threatens the effectiveness of current therapeutic options.

项与头孢吡肟/他尼硼巴坦相关的新闻（医药）

2025-08-14

·PipelineReview

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

ALLSCHWIL, Switzerland I August 14, 2025 I Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for the potential treatment of complicated urinary tract infections (cUTI), including pyelonephritis. Ceftibuten-ledaborbactam etzadroxil is the combination of ceftibuten, an orally bioavailable cephalosporin antibiotic, and ledaborbactam etzadroxil, the orally bioavailable prodrug of the novel beta-lactamase inhibitor ledaborbactam. The combination demonstrates bactericidal activity against Enterobacterales, including multidrug-resistant pathogens, the major cause of cUTI. [1] In the USA, cUTI account for more than 600,000 hospital admissions each year. [2] This underscores the significant clinical burden and need for effective oral treatment options, which may shorten or entirely avoid hospitalization. In preclinical and clinical phase 1 studies, ceftibuten and ledaborbactam etzadroxil were shown to be safe and well tolerated. [3] David Veitch, Chief Executive Officer of Basilea, said: “This agreement allows us to strengthen our late-stage clinical pipeline and supports our strategy of ensuring that we have a continuous stream of potential new product launches in the near-term future, positioning us for sustainable substantial revenue growth. Ceftibuten-ledaborbactam etzadroxil holds strong promise in addressing the critical unmet need for the oral treatment of cUTI caused by multidrug-resistant Gram-negative bacteria and represents a compelling global commercial opportunity. We expect starting a registrational phase 3 program in cUTI in about 18 months.” Under the terms of the agreement, Basilea will make an upfront payment and potential milestone payments in 2025. Following the successful completion of the phase 3 clinical development program and after the grant of regulatory approval and start of commercialization, Venatorx is eligible to receive tiered mid-single-digit royalties and additional potential milestone payments of up to USD 325 million in total, if all agreed commercial milestone events are triggered over the term of the contract. The transaction is expected to result in approximately CHF 15 million of additional research and development expenses in 2025, including the full upfront payment, all potential pre-commercial milestone payments and expected R&D expenses in 2025. Basilea will provide updated financial guidance for the full-year 2025, reflecting this transaction, with the half-year earnings report on August 19, 2025. About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections by multidrug-resistant bacterial pathogens. About ceftibuten-ledaborbactam etzadroxil Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. [4] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. About complicated urinary tract infections (cUTI) Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. [1] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48). About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx also developed cefepime-taniborbactam, an intravenous-only antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. The ceftibuten-ledaborbactam etzadroxil project has been funded in whole or in part with Federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C and the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050. For more information about Venatorx and its anti-infectives portfolio, please visit www.venatorx.com . About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com . References SOURCE: Basilea

临床3期引进/卖出上市批准临床1期快速通道

2024-05-23

·美通社

Access to Medicine Foundation的新报告显示，制药公司可以采取哪些措施来确保处于耐药性前线的患者能够获得正在开发的少数有前途的抗微生物药物

阿姆斯特丹 2024年5月23日 /美通社/ -- 开发替代抗生素和抗真菌药物来对抗超级细菌的竞赛严重不足，使世界各地的人们处于危险之中。但是，研发（R&D）的转变，包括对准入和管理规划的投资，可以对抗微生物药物耐药性（AMR）产生重大影响。由于大多数以研究为基础的大型制药公司不再活跃于抗微生物药物研发，因此上市的新疗法很少，这使得患者容易受到抗微生物药物耐药性快速传播的影响。尽管存在这种现实，但少数处于后期临床开发阶段的项目可能会产生重大影响。 A ccess to Medicine Foundation的新报告追踪了葛兰素史克、F2G、Innoviva、Venatorx（分别为gepotidacin、olorofim、zoliflodacin和cefepime-taniborbactam）和辉瑞最近批准的阿曲南阿维巴坦（Emblaveo®）管道中的五个此类项目。通过提供急需的药物来治疗耐药性淋病、尿路感染、腹腔内感染、呼吸道感染和侵入性真菌感染，这些项目每年总共可以挽救至少16万人的生命。尽管这些疾病影响着全球范围广泛的患者，但妇女和儿童，尤其是生活在低收入和中等收入国家（LMIC）的妇女和儿童，受到的影响尤其严重。 "在抗击耐药感染的竞赛中，我们的武器规模虽小但有效。我们在这场竞赛中获胜与失败的区别取决于公司如何为生活在耐药前线的人们提供机会。" — 医学准入基金会首席执行官贾亚斯里•艾耶。调查结果显示，各公司在其准入和管理计划中采用了多种策略，但结构化的预先计划尚未成为标准。令人鼓舞的是，在范围内的五家公司中，有四家——葛兰素史克、辉瑞、Innoviva和Venatorx——正在进行或启动直接针对儿童的临床试验，这表明在缩小成人和儿科准入差距方面取得了进展。五个低收入国家确定了注册承诺：中国、印度、墨西哥、南非和泰国。但是，对于范围内的113个中低收入国家中的108个，人们也面临着这些项目针对的疾病的沉重负担，目前尚不清楚在初步批准后是否会提供这些项目。该报告为重点公司确定了机遇和建议，并概述了全球利益相关者在抗微生物药物研发领域的可行措施，以促进广泛采用预先准入和管理规划。 "应对耐药性的巨大规模和速度是一个复杂的全球健康问题，需要制药公司在多个领域采取行动。这包括提供适当的准入和实施管理措施，以保障创新抗微生物药物的有效性。不这样做将限制解决耐药性的努力。"——准入医学基金会运营与研究总监玛丽恩•维尔霍夫。在全球卫生利益相关者为2024年联合国大会抗菌素耐药性高级别会议做准备之际，本报告是在关键时刻发布的，强调了需要注意的紧迫差距。在这里阅读报告。

微生物疗法临床研究

2024-05-23

·Outsourcing Pharma

What can pharma companies do to get promising antimicrobials to the frontlines of drug resistance?

According to the report, the race to create antibiotics and antifungals to conquer superbugs is falling perilously short, which the authors say is putting people across the world at risk. However, a shift in research and development (R&D), including investment in access and stewardship planning, can make a significant impact against antimicrobial resistance (AMR). As most large research-based pharmaceutical companies are no longer active in antimicrobial research and development (R&D), there are very few new treatments making it to market, leaving patients vulnerable to the rapid spread of AMR. Despite this reality, a handful of projects in late-stage clinical development could have a significant impact. Difficult-to-treat invasive, rare fungal mold infections The foundation is tracking five drugs which include gepotidacin, a small molecule commercialized by GSK with a leading phase 3 program in urinary tract infections and F2G’s olorofim, a first of the new orotomide class of antifungals in development for the treatment of difficult-to-treat invasive, rare fungal mold infections. Innoviva’s zoliflodacin is another treatment being tracked and is said to be one of the most promising new treatments for gonorrhoeae currently in phase 3 clinical trials. According to a report in Nature Scientific Reports, studies have found very little resistance to the drug currently circulating in strains, and in-vitro experiments demonstrated that it is difficult to induce resistance. Venatorx’s cefepime-taniborbactam is also under the foundation’s radar. The beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic is being developed for the treatment of complicated urinary tract infections and hospital acquired bacterial pneumonia. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Pfizer's recently approved aztreonam-avibactam (Emblaveo) is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant gram-negative bacteria, including metallo-β-lactamase-producing bacteria. Emblaveo was reviewed under European Medicines Agency accelerated assessment procedure, used when a pharmaceutical product is of major interest for public health and therapeutic innovation. People living on the frontlines of drug resistance Collectively, these projects could save at least 160,000 lives annually by providing much-needed medicines to treat drug-resistant gonorrhoea, urinary tract infections, intra-abdominal infections, respiratory infections, and invasive fungal infections. While these diseases affect a wide range of patients globally, women and children- especially those living in low-and middle-income countries (LMICs)- are disproportionately affected. Jayasree Iyer, CEO, at the Access to Medicine Foundation, said: “We have a small, but effective, arsenal in the race to combat drug-resistant infections. The difference between us winning or losing this race depends on how companies enable access to people living on the frontlines of drug resistance.” The foundation said that findings reveal that companies are employing diverse range of strategies within their access and stewardship plans but structured advance planning has not yet become standard. Encouragingly, it said, four of the five companies in scope, GSK, Pfizer, Innoviva, and Venatorx, are conducting or initiating clinical trials that directly target children, signalling progress in closing the gap between adult and paediatric access. Tackling the sheer scale and pace of drug resistance Commitments for registration were identified in five LMICs: China, India, Mexico, South Africa, and Thailand. However, for 108 of 113 LMICs in scope, where people also face high burdens of the diseases targeted by these projects, it is currently unclear whether any of them will be made available upon initial approval. The report identifies opportunities and recommendations for companies in focus and outlines actionable steps for global stakeholders in antimicrobial R&D to promote widespread adoption of advance access and stewardship planning. Marijn Verhoef, director of operations and research, at the Access to Medicine Foundation, said: “Tackling the sheer scale and pace of drug resistance is a complex global health issue that will require action from pharmaceutical companies across several areas. This includes providing appropriate access and implementing stewardship measures to safeguard the effectiveness of innovative antimicrobials. Failure to do this will limit efforts to tackle drug resistance.” The foundation added that as global health stakeholders prepare for 2024 UN General Assembly's High-level Meeting on AMR, this report comes at a crucial moment, emphasising the urgent gaps that need attention.

临床3期上市批准

100 项与头孢吡肟/他尼硼巴坦相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复杂的尿路感染	申请上市	美国	Venatorx Pharmaceuticals, Inc.	2023-08-15
肾盂肾炎	申请上市	美国	Venatorx Pharmaceuticals, Inc.	2023-08-15
医院获得性肺炎	临床3期	-	Venatorx Pharmaceuticals, Inc.	2025-06-01
呼吸机相关细菌性肺炎	临床3期	-	Venatorx Pharmaceuticals, Inc.	2025-06-01
急性肾盂肾炎	临床3期	美国	云顶新耀（北京）医药科技有限公司	2019-08-07
急性肾盂肾炎	临床3期	美国	Venatorx Pharmaceuticals, Inc.	2019-08-07
急性肾盂肾炎	临床3期	中国	Venatorx Pharmaceuticals, Inc.	2019-08-07
急性肾盂肾炎	临床3期	阿根廷	Venatorx Pharmaceuticals, Inc.	2019-08-07
急性肾盂肾炎	临床3期	阿根廷	云顶新耀（北京）医药科技有限公司	2019-08-07
急性肾盂肾炎	临床3期	巴西	Venatorx Pharmaceuticals, Inc.	2019-08-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03840148 (CERTAIN-1, Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床3期	泌尿道感染	436	Cefepime/taniborbactam	獵繭窪窪願膚鏇顧襯鑰(鹹簾鬱糧鑰顧鹹鹹壓鬱) = 蓋顧醖觸蓋醖壓簾簾獵顧窪夢醖膚範齋製糧簾 (壓鹹艱鹽齋膚選網廠鹽 ) 更多	积极	2024-02-15
NCT03840148 (CERTAIN-1, Corporate Publications) 人工标引	临床3期	复杂的尿路感染	661	Cefepime/Taniborbactam	廠鹹選鹹衊網網窪憲膚(顧簾鏇糧糧窪積壓壓憲) = 構齋窪蓋憲鏇齋鹽膚鹹糧構鏇淵壓積構糧觸襯 (遞鹽願顧願鬱鏇積顧觸 ) 更多	优效	2022-03-10
NCT03840148 (CERTAIN-1, Corporate Publications) 人工标引	临床3期	复杂的尿路感染	661	meropenem	廠鹹選鹹衊網網窪憲膚(顧簾鏇糧糧窪積壓壓憲) = 製壓淵衊遞醖餘憲壓醖糧構鏇淵壓積構糧觸襯 (遞鹽願顧願鬱鏇積顧觸 ) 更多	优效	2022-03-10